ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1312

Interstitial Pneumonia with Autoimmune Features (IPAF)-Nsip: Hurdles to Reclassification of Overlapping Ilds

Amaka Odonwodo1 and Aman Pande2, 1Internal Medicine, Cleveland Clinic, Cleveland, OH, 2Pulmonary Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Connective tissue diseases and interstitial lung disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster II: Interstitial Lung Disease, Still's Disease, FMF, Polychondritis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Interstitial lung disease (ILD) may occur in the presence of autoimmune elements without meeting criteria for a distinctive Connective Tissue Disease.

The European Respiratory Society/ American Thoracic Society proposed a term ‘interstitial pneumonia with autoimmune features’ (IPAF) to further classify these individuals based on a combination of features from three domains: clinical, serologic and pulmonary morphologic.

We sought to assess the incidence of IPAF previously classified as idiopathic interstitial pneumonia or ILD associated with undifferentiated connective tissue disease (UCTD). Hurdles in the reclassification process were also highlighted.

Methods:

Our institution’s pathology database was scanned for 10 years of surgical lung biopsy data. Patients with biopsy proven nonspecific interstitial pneumonia (NSIP) were studied. Their clinical and serologic data was collated. Cases with a prior diagnosis of idiopathic NSIP or ILD associated with UCTD were screened by the ERS/ATS criteria for IPAF and reclassified.

Results:

17 of 278 surgical lung biopsies performed from 2006 to 2016 for ILD were reported as NSIP. 41% of these NSIP cases were previously classified as idiopathic, 17.7 % as associated with UCTD and the remaining had established autoimmune etiologies for an ILD.

57% of the prior idiopathic cases were reclassified as IPAF and 100% of the prior UCTD were reclassified as IPAF. All cases met morphologic criteria (NSIP on lung biopsy), 57% had serologic criteria and 71% met clinical criteria. The serologic workup was incomplete in a few patients.

Conclusion:

Previous diagnoses of UCTD-ILD and Idiopathic NSIP may be reclassified as IPAF. This will help promote future research to guide management of this unique population. It is important to stress the need for serologic work up of ILD patients, to enable complete assessment and appropriate classification of patients.


Disclosure: A. Odonwodo, None; A. Pande, None.

To cite this abstract in AMA style:

Odonwodo A, Pande A. Interstitial Pneumonia with Autoimmune Features (IPAF)-Nsip: Hurdles to Reclassification of Overlapping Ilds [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/interstitial-pneumonia-with-autoimmune-features-ipaf-nsip-hurdles-to-reclassification-of-overlapping-ilds/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interstitial-pneumonia-with-autoimmune-features-ipaf-nsip-hurdles-to-reclassification-of-overlapping-ilds/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology